Clinical trials: Aortic Stenosis
Cardiovascular Diseases, Heart Diseases
Genetic Analysis of Familial Hypertrophic Cardiomyopathy
To map the genetic defect responsible for familial hypertrophic cardiomyopathy.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Myocardial Diseases, Cardiomyopathy, Hypertrophic
- Trial name
- NCT00005251
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Transcatheter Aortic Valve Replacement, Severe Symptomatic Calcified Native Aortic Valve Stenosis
Sentinel(TM) Post-Market Registry
The SENTINEL Post-Market Registry is a prospective, multi-center, registry using the CE-Marked Sentinel System in subjects with severe symptomatic calcified native aortic valve stenosis indicated for TAVR.
- Trial name
- NCT02255851
- Testing
- SENTINEL (Cerebral Protection System)
- Volunteers
- 300 people
- Sponsor
- Claret Medical
Aortic Valve Replacement
PERCEVAL Pivotal Trial
The clinical investigation is designed as a prospective and non-randomised study on a maximum of 150 patients. This study will be conducted at Investigational Centres in the European Community.
- Trial name
- NCT00860730
- Testing
- Aortic valve replacement with Perceval aortic heart valve
- Where
- 9 sites in Belgium, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Corcym S.r.l
Adult Patients Undergoing Open Heart Replacement of the Aortic Valve for Aortic Stenosis or Insufficiency
Elimination of CO2-insufflation-induced Hypercarbia in Open Heart Surgery
The study aim was to evaluate if an additional separate venous reservoir eliminates CO2-insufflation induced hypercapnia and keeps sweep gas flow of the oxygenator constant during open heart surgery.
- Trial name
- NCT04202575
- Testing
- Tube clamping
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Karolinska University Hospital
Amyloidosis Cardiac, Aortic Stenosis, Severe
Analysis of Calcium Score of Severe Aortic Stenosis in Patients With and Without Cardiac Amyloidosis (CAUSATIVE Study)
The concomitant presence of cardiac amyloidosis (CA) in patients with aortic stenosis (AS) may challenge the estimation of stenosis degree.
- Trial name
- CAUSATIVE (NCT06066632)
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- University Hospital of Ferrara
Pneumonia, Lung Cancer
On Dose Efficiency of Modern CT-scanners in Chest Scans
CT scans of the chest / thorax are of great importance both in the initial diagnosis and in the follow-up of pulmonary or thoracic diseases.
- Conditions
- Pneumonia, Lung Cancer, Pulmonary Embolism, Pulmonary Disease
- Trial name
- NCT04996693
- Testing
- Imaging on Scanner with Spectral Imaging Capabilities, CT Scan using an Energy-Integrating Detector CT (128 slice MDCT), CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)
- Where
- Germany
- Volunteers
- 958 people
- Sponsor
- University Hospital Augsburg
Cardiomyopathies, Hypertrophic Cardiomyopathy
The SMARTER Cardiomyopathy Study
Cardiomyopathies are diseases of the heart muscle. Known genetic factors may account for some cardiomyopathy cases but there is still much to understand about the genetic and environmental causes and how the disease progresses.
- Conditions
- Cardiomyopathies, Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy
- Trial name
- SMARTER-CM (NCT05750147)
- Testing
- Blood Sample Collection
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Depression, Aortic Stenosis
Depression and Major Adverse Events in Older Patients Who Undergo a Transcatheter Aortic Valve Implantation
Depression, screened using the Geriatric Depression Scale (GDS) Short Form, has recently been found to be associated with a 3-fold increase in 1-year mortality after aortic valve replacement (AVR) in patients aged 70 or older.
- Trial name
- TAVIDEP (NCT03995914)
- Sponsor
- University Hospital, Montpellier
Aortic Stenosis (Treated With TAVI)
Effect of Preoperative Iron Isomaltoside 1000 Administration on Hemoglobin Concentration in Patients Undergoing Transcatheter Aortic Valve Implantation
Transcatheter aortic valve implantation (TAVI) is a standard procedure for severe aortic stenosis patients with moderate or higher risk of surgery.
- Trial name
- NCT04346004
- Testing
- Normal saline, Iron isomaltoside
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- Yonsei University
Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy, Cardiac Sarcoidosis, Hypertensive Heart Disease
- Trial name
- CHIEFTain (NCT06409585)
- Testing
- 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR, Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Platelet Function Tests, Predictive Value of Tests
Risk Stratification Post TAVI Using TEG
Transcatheter aortic valve implantation (TAVI) has become the standard of care in elderly patients at increased risk for surgical aortic valve replacement . However, the optimal antithrombotic strategy post TAVI is still unclear.
- Conditions
- Platelet Function Tests, Predictive Value of Tests, Thrombelastography, Cardiovascular Diseases
- Trial name
- RISTRATAVI (NCT03649594)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Torben Pottgiesser
Aortic Stenosis
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
- Trial name
- NCT03735667
- Testing
- ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System
- Where
- 75 sites in United States, Canada
- Volunteers
- 1,948 people
- Sponsor
- Boston Scientific Corporation
Transcatheter Aortic Valve Replacement (TAVR), Left Ventricular Hypertrophy
Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)
This is a multicenter, prospective, open-label, randomized, investigator-initiated trial evaluating whether angiotensin receptor blocker (ARB) therapy improves clinical outcomes in patients with severe aortic stenosis (AS) and…
- Conditions
- Transcatheter Aortic Valve Replacement (TAVR), Left Ventricular Hypertrophy, Severe Aortic Stenosis
- Trial name
- ARBITAR (NCT07735130)
- Testing
- Angiotensin Receptor Blocker (ARB)
- Where
- South Korea
- Volunteers
- 632 people
- Sponsor
- Seoul National University Hospital
Severe Aortic Stenosis, Iron-deficiency
Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
Iron deficiency is a prevalent nutritional deficiency and a common cause of anemia. Although iron deficiency is traditionally linked to anemia, iron deficiency is prevalent even in the absence of anaemia and in itself limits…
- Trial name
- IIISAS (NCT04206228)
- Testing
- Intravenous iron isomaltoside
- Where
- Norway
- Volunteers
- 149 people
- Sponsor
- Oslo University Hospital
Aortic Valve Stenosis
Pressure Gradient vs. Flow Relationships in Patients With Symptomatic Valvular Aortic Stenosis
The objective of the present study is to investigate to hemodynamic profile at rest and during peak exercise of patients with suspected severe aortic stenosis and to compare flow- and pressure changes between high gradient…
- Trial name
- PREFLOW (NCT05580237)
- Testing
- Simultaneous right and left heart catheterization
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Aarhus University Hospital Skejby
Aortic Valve Disease, Aortic Valve Stenosis
VitaFlow® Transcatheter Aortic Valve Replacement System Pre-market Trial Long Term Follow Up （VITAL）
This study is an observational study to evaluate the long-term safety and effectiveness of the valve system.
- Trial name
- VITAL (NCT05977257)
- Testing
- VitaFlow® Transcatheter Aortic Valve Replacement System
- Where
- 4 sites in China
- Volunteers
- 89 people
- Sponsor
- Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Hypertrophic Cardiomyopathy
Exercise Training in Hypertrophic Cardiomyopathy: (SAFE-HCM)
To explore the feasibility, safety, health and psychological benefits of a 12-week high intensity exercise programme in a young group of individuals with hypertrophic cardiomyopathy (HCM).
- Trial name
- SAFE-HCM (NCT05459467)
- Testing
- Exercise
- Where
- 3 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- St George's, University of London
Aortic Stenosis
Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis
Abundant evidence suggests that Angiotensin Converting Enzyme (ACE) inhibition potentially could reduce the hazardous effects of aortic stenosis and improve haemodynamics.
- Trial name
- NCT00252317
- Testing
- Captopril and Trandolapril, Captopril Test Dose and Trandolapril
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hypertrophic Cardiomyopathy
Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy
Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter monitor.
- Trial name
- PRIMARy (NCT02994615)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hypertrophic Cardiomyopathy, Hearing Loss
Refining Information Technology Support for Genetics in Medicine
The clinical use of genetic testing is expanding and, as a result, the number of variants identified in patients is growing. Knowledge of the clinical impact of these variants improves over time.
- Conditions
- Hypertrophic Cardiomyopathy, Hearing Loss, Cancer
- Trial name
- RISGIM (NCT01225978)
- Testing
- GeneInsight Clinic (GIC)
- Where
- 9 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.